Women's health drug is the health drug specifically for women.
Market Analysis and Insights: Global Women's Health Drugs Market
Due to the COVID-19 pandemic, the global Women's Health Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Postmenopausal Osteoporosis Drug accounting for % of the Women's Health Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Little Girls segment is altered to an % CAGR throughout this forecast period.
China Women's Health Drugs market size is valued at US$ million in 2021, while the US and Europe Women's Health Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Women's Health Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Women's Health Drugs include AbbVie Inc, Allergan Plc, Bayer AG, GlaxoSmithKline, Merck & Co., Pfizer and Therapeutics MD, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Women's Health Drugs Scope and Segment
Women's Health Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Women's Health Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Postmenopausal Osteoporosis Drug
Infertility Drug
Endometriosis Drug
Contraceptives Drug
Menopause Drug
Polycystic Ovary Syndrome Drug
Other
Segment by Application
Little Girls
Young Women
Elderly Women
By Company
AbbVie Inc
Allergan Plc
Bayer AG
GlaxoSmithKline
Merck & Co.
Pfizer
Therapeutics MD
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Market Analysis and Insights: Global Women's Health Drugs Market
Due to the COVID-19 pandemic, the global Women's Health Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Postmenopausal Osteoporosis Drug accounting for % of the Women's Health Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Little Girls segment is altered to an % CAGR throughout this forecast period.
China Women's Health Drugs market size is valued at US$ million in 2021, while the US and Europe Women's Health Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Women's Health Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Women's Health Drugs include AbbVie Inc, Allergan Plc, Bayer AG, GlaxoSmithKline, Merck & Co., Pfizer and Therapeutics MD, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Women's Health Drugs Scope and Segment
Women's Health Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Women's Health Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Postmenopausal Osteoporosis Drug
Infertility Drug
Endometriosis Drug
Contraceptives Drug
Menopause Drug
Polycystic Ovary Syndrome Drug
Other
Segment by Application
Little Girls
Young Women
Elderly Women
By Company
AbbVie Inc
Allergan Plc
Bayer AG
GlaxoSmithKline
Merck & Co.
Pfizer
Therapeutics MD
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.